Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on March 6, 2024, covering events occurring on March 6 and March 7, 2024. The company is incorporated in Delaware and trades on the NASDAQ under the symbols ATNF (Common Stock) and ATNFW (Warrants).
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to a specific equity transaction:
- Cash Proceeds: $254.60 total from warrant exercises.
- Shares Issued: 134,000 shares of common stock (72,000 on March 6 and 62,000 on March 7).
- Outstanding Shares: Approximately 852,758 shares of common stock issued and outstanding following the transaction.
- Warrants Outstanding: Zero pre-funded warrants remain outstanding.
Material Changes
The primary material change reported is the full exercise of pre-funded warrants by a holder. This transaction was executed at an exercise price of $0.0019 per share. The share counts reflect adjustments for a 1-for-19 reverse stock split that became effective on February 28, 2024. The exercise was exempt from registration under Section 4(a)(2) of the Securities Act, though the resale of the shares was registered.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The document is strictly a disclosure of the unregistered sales of equity securities and the resulting capitalization changes.
Investor Verification Checklist
- Verify the company name is 180 Life Sciences Corp. (ATNF), as the request metadata incorrectly listed "Forum Markets Inc."
- Confirm the impact of the 1-for-19 reverse stock split (effective Feb 28, 2024) on historical share counts and per-share metrics.
- Note that the cash proceeds from this specific transaction ($254.60) are nominal and do not reflect the company's overall liquidity position.
- Confirm that no pre-funded warrants remain outstanding, which may alter future dilution profiles.